Baker Tilly Wealth Management LLC Has $808,000 Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Baker Tilly Wealth Management LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,554 shares of the medical research company’s stock after selling 46 shares during the period. Baker Tilly Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $808,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in TMO. MGO One Seven LLC increased its position in Thermo Fisher Scientific by 3.1% in the 2nd quarter. MGO One Seven LLC now owns 3,612 shares of the medical research company’s stock valued at $1,997,000 after acquiring an additional 110 shares in the last quarter. LPL Financial LLC increased its stake in shares of Thermo Fisher Scientific by 4.6% in the 2nd quarter. LPL Financial LLC now owns 217,770 shares of the medical research company’s stock valued at $120,427,000 after buying an additional 9,578 shares during the period. Qsemble Capital Management LP acquired a new position in shares of Thermo Fisher Scientific during the second quarter valued at $2,219,000. Johnson Investment Counsel Inc. boosted its holdings in Thermo Fisher Scientific by 3.4% in the second quarter. Johnson Investment Counsel Inc. now owns 9,359 shares of the medical research company’s stock valued at $5,176,000 after acquiring an additional 309 shares during the last quarter. Finally, Oppenheimer & Co. Inc. raised its holdings in Thermo Fisher Scientific by 0.5% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 31,433 shares of the medical research company’s stock worth $17,382,000 after purchasing an additional 144 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the transaction, the chief executive officer now owns 121,192 shares of the company’s stock, valued at approximately $67,175,513.68. This represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the sale, the executive vice president now directly owns 16,663 shares in the company, valued at $9,333,946.08. This trade represents a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,150 shares of company stock valued at $25,954,465 over the last three months. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded down $2.78 on Friday, reaching $542.15. 972,419 shares of the company’s stock were exchanged, compared to its average volume of 1,642,158. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The company has a fifty day moving average of $530.21 and a 200-day moving average of $568.07. The company has a market capitalization of $207.37 billion, a price-to-earnings ratio of 33.99, a PEG ratio of 3.54 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. During the same period in the previous year, the firm earned $5.69 EPS. The company’s quarterly revenue was up .2% compared to the same quarter last year. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its board has authorized a stock buyback program on Friday, November 15th that permits the company to buyback $4.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TMO. Bank of America lowered their price target on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research report on Friday, December 13th. UBS Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research note on Monday, September 16th. Barclays cut their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Stephens assumed coverage on Thermo Fisher Scientific in a research note on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price objective on the stock. Finally, Evercore ISI cut their price objective on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $650.52.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.